La Jolla Pharmaceutical Company Revenue and Competitors
Estimated Revenue & Valuation
- La Jolla Pharmaceutical Company's estimated annual revenue is currently $15M per year.
- La Jolla Pharmaceutical Company's estimated revenue per employee is $125,000
- La Jolla Pharmaceutical Company's total funding is $190.9M.
Employee Data
- La Jolla Pharmaceutical Company has 120 Employees.
- La Jolla Pharmaceutical Company grew their employee count by -15% last year.
La Jolla Pharmaceutical Company's People
| Name | Title | Email/Phone |
|---|
La Jolla Pharmaceutical Company Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.4M | 70 | -8% | $53M | N/A |
#2 | $32.4M | 167 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.8M | 18 | 13% | N/A | N/A |
#5 | $0.8M | 5 | -50% | N/A | N/A |
#6 | $0.8M | 10 | 0% | N/A | N/A |
#7 | $14M | 90 | -12% | N/A | N/A |
#8 | $0.4M | 336 | 10% | $236.7M | N/A |
#9 | $4.8M | 62 | -74% | $160M | N/A |
#10 | $3.7M | 24 | -8% | N/A | N/A |
What Is La Jolla Pharmaceutical Company?
La Jolla Pharmaceutical Company (LJPC) is a biopharmaceutical company that is focused on the research and development of highly specific therapeutics for the treatment of certain life-threatening antibody-mediated diseases. These diseases, including autoimmune conditions such as lupus and antibody-mediated stroke, are caused by abnormal B cell production of antibodies that attack healthy tissues. The Company\'s drug candidates, called Toleragens, are designed to treat the underlying cause of many antibody-mediated diseases without the severe, adverse side effects common to other treatments. The Company is analyzing data from a Phase III clinical trial of its lupus drug candidate, LJP 394, and its clinical drug candidate for the treatment of antibody-mediated thrombosis, known as LJP 1082, is currently being evaluated in toxicology studies that are required prior to the initiation of clinical trials.
keywords:N/A
$190.9M
Total Funding
120
Number of Employees
$15M
Revenue (est)
-15%
Employee Growth %
N/A
Valuation
N/A
Accelerator
La Jolla Pharmaceutical Company News
... GlaxoSmithKline plc, Incyte Corporation, Gamida Cell, Kiadis Pharma, La Jolla Pharmaceutical Company, IONIS Pharmaceuticals.
Daiichi Sankyo Company Ltd; La Jolla Pharmaceutical Company; Oncodesign Sa; Tolero Pharmaceuticals Inc Activin Receptor Type 1 Market Breakdown by Type: Ljpc...
... Genzyme Corporation, La Jolla Pharmaceutical Company, Merck & Co., Inc. ... vendor landscape and important company profiles,medical disposable market...
Other Companies in San Diego
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $21.6M | 120 | 25% | N/A |
#2 | $42.4M | 120 | 19% | N/A |
#3 | $12.2M | 120 | 9% | $70M |
#4 | $18.6M | 120 | -3% | $156.1M |
#5 | $18M | 120 | -3% | N/A |